Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

GLAXOSMITHKLINE PHARMACEUTICALS LTD.

NSE : GLAXOBSE : 500660ISIN CODE : INE159A01016Industry : Pharmaceuticals & DrugsHouse : Glaxosmithkline - MNC

BSE2093.85-9.7 (-0.46 %)

PREV CLOSE ( ) 2103.55

OPEN PRICE ( ) 2105.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 8701

TODAY'S LOW / HIGH ( )2078.40 2144.55

52 WK LOW / HIGH ( )1242 2649.95

NSE2095.35-6.4 (-0.3 %)

PREV CLOSE( ) 2101.75

OPEN PRICE ( ) 2122.00

BID PRICE (QTY) 2095.35 (47)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 101606

TODAY'S LOW / HIGH( ) 2078.10 2145.00

52 WK LOW / HIGH ( )1241.15 2524

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 13-11 1924

Management Info

R S Karnad - Chairman Bhushan Akshikar - Managing Director

Registered Office

Address Gsk House, Dr. Annie Besant Road,Worli,,
Mumbai,
Maharashtra-400030

Phone 022-24959595

Email in.investorquery@gsk.com

Website www.gsk-india.com

Registrars Details

K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)

Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad

Listing : BSE, NSE, MCX

NEWS

24Apr GlaxoSmithKline Pharmaceuticals inform
Pursuant to Regulation 39 and other application regulations of SEBI (Lis..

16Apr GlaxoSmithKline Pharmaceuticals inform
Pursuant to Regulation 39 and other application regulations of SEBI (Lis..

05Apr GlaxoSmithKline Pharmaceuticals inform
Pursuant to Regulation 39 and other application regulations of SEBI (Lis..

04Apr Glaxosmithkline Pharmaceuticals inform
Pursuant to Regulation 39 and other application regulations of SEBI (Lis..

02Apr Glaxosmithkline Pharmaceuticals inform
In Compliance with Regulation 74(5) of SEBI (Depositories and Participan..

Financials

Rs. in Millions

	QTR Dec 23	ANNUAL 23
Net Profit	454.900000000001	6077.5
Gross Profit	651.100000000001	8323.8
Operating Profit	2458.5	9009.3
Net Sales	8049.8	32163.4

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Ajanta Pharma (BSE) 2377.00 (6.44%)	M.Cap ( in Cr)29930.39
Alkem Laboratories (BSE) 4899.45 (2.36%)	M.Cap ( in Cr)58580.27
Astrazeneca Pharma I (BSE) 5424.45 (1.70%)	M.Cap ( in Cr)13561.13
Dr. Reddy's Lab (BSE) 6349.95 (0.98%)	M.Cap ( in Cr)105928.76
Torrent Pharma (BSE) 2732.60 (2.20%)	M.Cap ( in Cr)92483.60

Shareholding Pattern

	PROMOTERS	75%
	NON-INSTITUTION	13.62%
	MUTUAL FUNDS/UTI	4.51%
	FI/BANKS/INSURANCE	3.27%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
Quant Healthcare Fu...	3.39
Aditya Birla SL MNC...	3.02
Nippon India Pharma...	2.33
Quant Large & Mid C...	2.08
UTI Nifty Midcap 15...	1.83
DSP Nifty Midcap 15...	1.83
DSP Nifty Midcap 15...	1.83

Risk Disclosures on Derivatives

Smart Quotes

GLAXOSMITHKLINE PHARMACEUTICALS LTD.